Adebrelimab and Bevacizumab Plus Platinum Chemotherapy in Triple-Negative Breast Cancer With Brain Metastases - Takeaway - MDSpire
From the Journals
Clinical Guidelines

Adebrelimab and Bevacizumab Plus Platinum Chemotherapy in Triple-Negative Breast Cancer With Brain Metastases

In a Chinese phase II study (ABC) reported in the Journal of Clinical Oncology, Li et al found that the combination of the PD-L1 inhibitor adebrelimab, bevacizumab, and cisplatin or carboplatin showed...

Share

  • 1

    Phase II study evaluated adebrelimab, bevacizumab, and cisplatin/carboplatin.

  • 2

    35 patients with triple-negative breast cancer and active brain metastases.

  • 3

    CNS objective response rate was 77.1%.

  • 4

    Median overall progression-free survival was 8.3 months.

  • 5

    Treatment-related adverse events: anemia (80%), hypomagnesemia (74.3%).

  • 6

    Complete response observed in 5 patients.

  • 7

    No treatment-related deaths reported.

Original Source(s)

Adebrelimab and Bevacizumab Plus Platinum Chemotherapy in Triple-Negative Breast Cancer With Brain Metastases

  • by Matthew Stenger

  • April 22, 2026

Related Content

CD40 Overexpression Emerges as a Potential Biomarker for Angioimmunoblastic T-Cell Lymphoma

Researchers at The University of Texas MD Anderson Cancer Center have identified CD40 overexpression as a potential prognostic biomarker for angioimmunoblastic T-cell lymphoma, a rare subtype of non-H...

First-Line Zongertinib in Advanced <em>HER2</em>-Mutant NSCLC

In a phase IA to IB trial reported in The New England Journal of Medicine, Heymach et al found that first-line zongertinib was active in patients with advanced or metastatic HER2-mutant non–small cell...

Lung Cancer’s Hidden Layers

Study shows that tumor complexity can limit biopsy-based diagnosis

  • April 22, 2026

  • 2 min